BRCA1-deficient and BRCA2-deficient tumors have distinct T cell and myeloid populations that impact response to immunotherapy [17], and low expression of BRCA1 protein in breast tumors is associated with increased CD8+ T cell infiltration, higher tumor proliferation, and poor survival [18]. Here, BRCA1 is linked to neoplasm.